Source 1review2018Parasitology
Toolkit/whole genome screening of gene knockout mutants
whole genome screening of gene knockout mutants
Also known as: whole genome screening
Taxonomy: Technique Branch / Method. Workflows sit above the mechanism and technique branches rather than replacing them.
Summary
Whole-genome screening of gene knockout mutants in Toxoplasma gondii is a CRISPR/Cas9-based assay method for generating and interrogating genome-scale loss-of-function mutant populations. The cited review identifies this as a recent use of CRISPR/Cas9 in an apicomplexan parasite.
Usefulness & Problems
Why this is useful
This method is useful for functional interrogation of genes at genome scale in T. gondii through knockout-based screening. The evidence supports its value as part of the rapid adoption of CRISPR/Cas9 in apicomplexan parasite research, but does not provide assay performance details.
Problem solved
It addresses the problem of performing whole-genome loss-of-function screening in T. gondii using targeted gene disruption. The supplied evidence does not specify the exact phenotypes, selection schemes, or screening outputs measured.
Problem links
Need better screening or enrichment leverage
DerivedWhole-genome screening of gene knockout mutants in Toxoplasma gondii is a CRISPR/Cas9-based assay method for generating and interrogating genome-scale loss-of-function mutant populations. The cited review identifies this as a recent application of CRISPR/Cas9 in apicomplexan parasites.
Need conditional recombination or state switching
DerivedWhole-genome screening of gene knockout mutants in Toxoplasma gondii is a CRISPR/Cas9-based assay method for generating and interrogating genome-scale loss-of-function mutant populations. The cited review identifies this as a recent application of CRISPR/Cas9 in apicomplexan parasites.
Need controllable genome or transcript editing
DerivedWhole-genome screening of gene knockout mutants in Toxoplasma gondii is a CRISPR/Cas9-based assay method for generating and interrogating genome-scale loss-of-function mutant populations. The cited review identifies this as a recent application of CRISPR/Cas9 in apicomplexan parasites.
Taxonomy & Function
Primary hierarchy
Technique Branch
Method: A concrete measurement method used to characterize an engineered system.
Mechanisms
crispr/cas9-mediated genome editingcrispr/cas9-mediated genome editinggene knockoutgene knockoutselection/enrichment-based functional screeningselection/enrichment-based functional screeningTarget processes
editingrecombinationselectionImplementation Constraints
cofactor dependency: cofactor requirement unknownencoding mode: genetically encodedimplementation constraint: context specific validationoperating role: sensor
Implementation is supported at the level of CRISPR/Cas9-mediated generation and screening of gene knockout mutants in T. gondii. The supplied evidence does not report guide design, delivery format, selectable markers, library construction, or readout methodology.
The evidence is limited to a review-level statement that this application was recently used in T. gondii, without experimental parameters, benchmark data, or validation outcomes. The same review notes that newer CRISPR/Cas9 variations had not yet been implemented in apicomplexans at that time, indicating that the technology's full potential remained unrealized.
Validation
Cell-freeBacteriaMammalianMouseHumanTherapeuticIndep. Replication
Supporting Sources
Ranked Claims
CRISPR/Cas9 rapidly became an essential component of research on apicomplexan parasites after its first reported application in this group.
this technology has rapidly become an essential component of research on apicomplexan parasites
CRISPR/Cas9 rapidly became an essential component of research on apicomplexan parasites after its first reported application in this group.
this technology has rapidly become an essential component of research on apicomplexan parasites
CRISPR/Cas9 rapidly became an essential component of research on apicomplexan parasites after its first reported application in this group.
this technology has rapidly become an essential component of research on apicomplexan parasites
CRISPR/Cas9 rapidly became an essential component of research on apicomplexan parasites after its first reported application in this group.
this technology has rapidly become an essential component of research on apicomplexan parasites
CRISPR/Cas9 rapidly became an essential component of research on apicomplexan parasites after its first reported application in this group.
this technology has rapidly become an essential component of research on apicomplexan parasites
CRISPR/Cas9 rapidly became an essential component of research on apicomplexan parasites after its first reported application in this group.
this technology has rapidly become an essential component of research on apicomplexan parasites
CRISPR/Cas9 rapidly became an essential component of research on apicomplexan parasites after its first reported application in this group.
this technology has rapidly become an essential component of research on apicomplexan parasites
CRISPR/Cas9 rapidly became an essential component of research on apicomplexan parasites after its first reported application in this group.
this technology has rapidly become an essential component of research on apicomplexan parasites
CRISPR/Cas9 rapidly became an essential component of research on apicomplexan parasites after its first reported application in this group.
this technology has rapidly become an essential component of research on apicomplexan parasites
CRISPR/Cas9 rapidly became an essential component of research on apicomplexan parasites after its first reported application in this group.
this technology has rapidly become an essential component of research on apicomplexan parasites
New variations of CRISPR/Cas9 had not yet been implemented in apicomplexans at the time of the review, and the technology's full potential remained unrealized pending integration of new variations and innovations.
we consider new variations of CRISPR/Cas9 that have yet to be implemented in apicomplexans... the full potential of this technology is yet to be realized as new variations and innovations are integrated into the field
New variations of CRISPR/Cas9 had not yet been implemented in apicomplexans at the time of the review, and the technology's full potential remained unrealized pending integration of new variations and innovations.
we consider new variations of CRISPR/Cas9 that have yet to be implemented in apicomplexans... the full potential of this technology is yet to be realized as new variations and innovations are integrated into the field
New variations of CRISPR/Cas9 had not yet been implemented in apicomplexans at the time of the review, and the technology's full potential remained unrealized pending integration of new variations and innovations.
we consider new variations of CRISPR/Cas9 that have yet to be implemented in apicomplexans... the full potential of this technology is yet to be realized as new variations and innovations are integrated into the field
New variations of CRISPR/Cas9 had not yet been implemented in apicomplexans at the time of the review, and the technology's full potential remained unrealized pending integration of new variations and innovations.
we consider new variations of CRISPR/Cas9 that have yet to be implemented in apicomplexans... the full potential of this technology is yet to be realized as new variations and innovations are integrated into the field
New variations of CRISPR/Cas9 had not yet been implemented in apicomplexans at the time of the review, and the technology's full potential remained unrealized pending integration of new variations and innovations.
we consider new variations of CRISPR/Cas9 that have yet to be implemented in apicomplexans... the full potential of this technology is yet to be realized as new variations and innovations are integrated into the field
New variations of CRISPR/Cas9 had not yet been implemented in apicomplexans at the time of the review, and the technology's full potential remained unrealized pending integration of new variations and innovations.
we consider new variations of CRISPR/Cas9 that have yet to be implemented in apicomplexans... the full potential of this technology is yet to be realized as new variations and innovations are integrated into the field
New variations of CRISPR/Cas9 had not yet been implemented in apicomplexans at the time of the review, and the technology's full potential remained unrealized pending integration of new variations and innovations.
we consider new variations of CRISPR/Cas9 that have yet to be implemented in apicomplexans... the full potential of this technology is yet to be realized as new variations and innovations are integrated into the field
New variations of CRISPR/Cas9 had not yet been implemented in apicomplexans at the time of the review, and the technology's full potential remained unrealized pending integration of new variations and innovations.
we consider new variations of CRISPR/Cas9 that have yet to be implemented in apicomplexans... the full potential of this technology is yet to be realized as new variations and innovations are integrated into the field
New variations of CRISPR/Cas9 had not yet been implemented in apicomplexans at the time of the review, and the technology's full potential remained unrealized pending integration of new variations and innovations.
we consider new variations of CRISPR/Cas9 that have yet to be implemented in apicomplexans... the full potential of this technology is yet to be realized as new variations and innovations are integrated into the field
New variations of CRISPR/Cas9 had not yet been implemented in apicomplexans at the time of the review, and the technology's full potential remained unrealized pending integration of new variations and innovations.
we consider new variations of CRISPR/Cas9 that have yet to be implemented in apicomplexans... the full potential of this technology is yet to be realized as new variations and innovations are integrated into the field
CRISPR/Cas9 has been used for seminal genetic manipulations of Cryptosporidium species.
highlight its use for seminal genetic manipulations of Cryptosporidium spp.
CRISPR/Cas9 has been used for seminal genetic manipulations of Cryptosporidium species.
highlight its use for seminal genetic manipulations of Cryptosporidium spp.
CRISPR/Cas9 has been used for seminal genetic manipulations of Cryptosporidium species.
highlight its use for seminal genetic manipulations of Cryptosporidium spp.
CRISPR/Cas9 has been used for seminal genetic manipulations of Cryptosporidium species.
highlight its use for seminal genetic manipulations of Cryptosporidium spp.
CRISPR/Cas9 has been used for seminal genetic manipulations of Cryptosporidium species.
highlight its use for seminal genetic manipulations of Cryptosporidium spp.
CRISPR/Cas9 has been used for seminal genetic manipulations of Cryptosporidium species.
highlight its use for seminal genetic manipulations of Cryptosporidium spp.
CRISPR/Cas9 has been used for seminal genetic manipulations of Cryptosporidium species.
highlight its use for seminal genetic manipulations of Cryptosporidium spp.
CRISPR/Cas9 has been used for seminal genetic manipulations of Cryptosporidium species.
highlight its use for seminal genetic manipulations of Cryptosporidium spp.
CRISPR/Cas9 has been used for seminal genetic manipulations of Cryptosporidium species.
highlight its use for seminal genetic manipulations of Cryptosporidium spp.
CRISPR/Cas9 has been used for seminal genetic manipulations of Cryptosporidium species.
highlight its use for seminal genetic manipulations of Cryptosporidium spp.
The review documents implementation of CRISPR/Cas9 in apicomplexan parasites, especially Plasmodium spp. and Toxoplasma gondii.
documenting its implementation in apicomplexan parasites, especially Plasmodium spp. and Toxoplasma gondii
The review documents implementation of CRISPR/Cas9 in apicomplexan parasites, especially Plasmodium spp. and Toxoplasma gondii.
documenting its implementation in apicomplexan parasites, especially Plasmodium spp. and Toxoplasma gondii
The review documents implementation of CRISPR/Cas9 in apicomplexan parasites, especially Plasmodium spp. and Toxoplasma gondii.
documenting its implementation in apicomplexan parasites, especially Plasmodium spp. and Toxoplasma gondii
The review documents implementation of CRISPR/Cas9 in apicomplexan parasites, especially Plasmodium spp. and Toxoplasma gondii.
documenting its implementation in apicomplexan parasites, especially Plasmodium spp. and Toxoplasma gondii
The review documents implementation of CRISPR/Cas9 in apicomplexan parasites, especially Plasmodium spp. and Toxoplasma gondii.
documenting its implementation in apicomplexan parasites, especially Plasmodium spp. and Toxoplasma gondii
The review documents implementation of CRISPR/Cas9 in apicomplexan parasites, especially Plasmodium spp. and Toxoplasma gondii.
documenting its implementation in apicomplexan parasites, especially Plasmodium spp. and Toxoplasma gondii
The review documents implementation of CRISPR/Cas9 in apicomplexan parasites, especially Plasmodium spp. and Toxoplasma gondii.
documenting its implementation in apicomplexan parasites, especially Plasmodium spp. and Toxoplasma gondii
The review documents implementation of CRISPR/Cas9 in apicomplexan parasites, especially Plasmodium spp. and Toxoplasma gondii.
documenting its implementation in apicomplexan parasites, especially Plasmodium spp. and Toxoplasma gondii
The review documents implementation of CRISPR/Cas9 in apicomplexan parasites, especially Plasmodium spp. and Toxoplasma gondii.
documenting its implementation in apicomplexan parasites, especially Plasmodium spp. and Toxoplasma gondii
The review documents implementation of CRISPR/Cas9 in apicomplexan parasites, especially Plasmodium spp. and Toxoplasma gondii.
documenting its implementation in apicomplexan parasites, especially Plasmodium spp. and Toxoplasma gondii
CRISPR/Cas9 has been used for whole-genome screening of gene knockout mutants in Toxoplasma gondii.
the recent use of CRISPR/Cas9 for whole genome screening of gene knockout mutants in T. gondii
CRISPR/Cas9 has been used for whole-genome screening of gene knockout mutants in Toxoplasma gondii.
the recent use of CRISPR/Cas9 for whole genome screening of gene knockout mutants in T. gondii
CRISPR/Cas9 has been used for whole-genome screening of gene knockout mutants in Toxoplasma gondii.
the recent use of CRISPR/Cas9 for whole genome screening of gene knockout mutants in T. gondii
CRISPR/Cas9 has been used for whole-genome screening of gene knockout mutants in Toxoplasma gondii.
the recent use of CRISPR/Cas9 for whole genome screening of gene knockout mutants in T. gondii
CRISPR/Cas9 has been used for whole-genome screening of gene knockout mutants in Toxoplasma gondii.
the recent use of CRISPR/Cas9 for whole genome screening of gene knockout mutants in T. gondii
CRISPR/Cas9 has been used for whole-genome screening of gene knockout mutants in Toxoplasma gondii.
the recent use of CRISPR/Cas9 for whole genome screening of gene knockout mutants in T. gondii
CRISPR/Cas9 has been used for whole-genome screening of gene knockout mutants in Toxoplasma gondii.
the recent use of CRISPR/Cas9 for whole genome screening of gene knockout mutants in T. gondii
CRISPR/Cas9 has been used for whole-genome screening of gene knockout mutants in Toxoplasma gondii.
the recent use of CRISPR/Cas9 for whole genome screening of gene knockout mutants in T. gondii
CRISPR/Cas9 has been used for whole-genome screening of gene knockout mutants in Toxoplasma gondii.
the recent use of CRISPR/Cas9 for whole genome screening of gene knockout mutants in T. gondii
CRISPR/Cas9 has been used for whole-genome screening of gene knockout mutants in Toxoplasma gondii.
the recent use of CRISPR/Cas9 for whole genome screening of gene knockout mutants in T. gondii
CRISPR/Cas9 has been used for whole-genome screening of gene knockout mutants in Toxoplasma gondii.
the recent use of CRISPR/Cas9 for whole genome screening of gene knockout mutants in T. gondii
CRISPR/Cas9 has been used for whole-genome screening of gene knockout mutants in Toxoplasma gondii.
the recent use of CRISPR/Cas9 for whole genome screening of gene knockout mutants in T. gondii
CRISPR/Cas9 has been used for whole-genome screening of gene knockout mutants in Toxoplasma gondii.
the recent use of CRISPR/Cas9 for whole genome screening of gene knockout mutants in T. gondii
CRISPR/Cas9 has been used for whole-genome screening of gene knockout mutants in Toxoplasma gondii.
the recent use of CRISPR/Cas9 for whole genome screening of gene knockout mutants in T. gondii
CRISPR/Cas9 has been used for whole-genome screening of gene knockout mutants in Toxoplasma gondii.
the recent use of CRISPR/Cas9 for whole genome screening of gene knockout mutants in T. gondii
CRISPR/Cas9 has been used for whole-genome screening of gene knockout mutants in Toxoplasma gondii.
the recent use of CRISPR/Cas9 for whole genome screening of gene knockout mutants in T. gondii
CRISPR/Cas9 has been used for whole-genome screening of gene knockout mutants in Toxoplasma gondii.
the recent use of CRISPR/Cas9 for whole genome screening of gene knockout mutants in T. gondii
CRISPR/Cas9 has been used for whole-genome screening of gene knockout mutants in Toxoplasma gondii.
the recent use of CRISPR/Cas9 for whole genome screening of gene knockout mutants in T. gondii
CRISPR/Cas9 has been used for whole-genome screening of gene knockout mutants in Toxoplasma gondii.
the recent use of CRISPR/Cas9 for whole genome screening of gene knockout mutants in T. gondii
CRISPR/Cas9 has been used for whole-genome screening of gene knockout mutants in Toxoplasma gondii.
the recent use of CRISPR/Cas9 for whole genome screening of gene knockout mutants in T. gondii
CRISPR/Cas9 has been used for whole-genome screening of gene knockout mutants in Toxoplasma gondii.
the recent use of CRISPR/Cas9 for whole genome screening of gene knockout mutants in T. gondii
CRISPR/Cas9 has been used for whole-genome screening of gene knockout mutants in Toxoplasma gondii.
the recent use of CRISPR/Cas9 for whole genome screening of gene knockout mutants in T. gondii
CRISPR/Cas9 has been used for whole-genome screening of gene knockout mutants in Toxoplasma gondii.
the recent use of CRISPR/Cas9 for whole genome screening of gene knockout mutants in T. gondii
CRISPR/Cas9 has been used for whole-genome screening of gene knockout mutants in Toxoplasma gondii.
the recent use of CRISPR/Cas9 for whole genome screening of gene knockout mutants in T. gondii
CRISPR/Cas9 has been used for whole-genome screening of gene knockout mutants in Toxoplasma gondii.
the recent use of CRISPR/Cas9 for whole genome screening of gene knockout mutants in T. gondii
CRISPR/Cas9 has been used for whole-genome screening of gene knockout mutants in Toxoplasma gondii.
the recent use of CRISPR/Cas9 for whole genome screening of gene knockout mutants in T. gondii
CRISPR/Cas9 has been used for whole-genome screening of gene knockout mutants in Toxoplasma gondii.
the recent use of CRISPR/Cas9 for whole genome screening of gene knockout mutants in T. gondii
Approval Evidence
1 source1 linked approval claimfirst-pass slug whole-genome-screening-of-gene-knockout-mutants
We also discuss the recent use of CRISPR/Cas9 for whole genome screening of gene knockout mutants in T. gondii
Source:
screening applicationsupports
CRISPR/Cas9 has been used for whole-genome screening of gene knockout mutants in Toxoplasma gondii.
the recent use of CRISPR/Cas9 for whole genome screening of gene knockout mutants in T. gondii
Source:
Comparisons
Source-backed strengths
A key strength is that it extends CRISPR/Cas9 from single-gene manipulation to whole-genome screening of knockout mutants in T. gondii. The review also states that CRISPR/Cas9 rapidly became an essential component of apicomplexan parasite research, supporting the platform's broad relevance in this organismal group.
Compared with chromatin in vivo imaging
whole genome screening of gene knockout mutants and chromatin in vivo imaging address a similar problem space because they share editing, recombination, selection.
Shared frame: same top-level item type; shared target processes: editing, recombination, selection
Compared with epigenetic element screening
whole genome screening of gene knockout mutants and epigenetic element screening address a similar problem space because they share editing, recombination, selection.
Shared frame: same top-level item type; shared target processes: editing, recombination, selection
Compared with high throughput screening
whole genome screening of gene knockout mutants and high throughput screening address a similar problem space because they share editing, recombination, selection.
Shared frame: same top-level item type; shared target processes: editing, recombination, selection
Ranked Citations
- 1.